22:47 , Apr 24, 2018 |  BC Extra  |  Company News

Amgen considering risk-based Aimovig pricing

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers about risk-based contracts with Aimovig." This quarter, Amgen...
21:16 , Apr 24, 2018 |  BC Extra  |  Company News

Biogen looks to ex-U.S. markets for growth

Biogen Inc. (NASDAQ:BIIB) perceives greater long-term growth opportunities than anticipated in the EU and emerging markets, the company's CEO Michel Vounatsos said on its earnings call Tuesday, while noting that the U.S. market remains its...
14:50 , Apr 6, 2018 |  BC Week In Review  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
22:09 , Apr 5, 2018 |  BC Extra  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for biotechs...
20:49 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Fosun's biosimilar unit to raise $190M

Shanghai Henlius Biotech Inc. (Shanghai, China) said on Dec. 21, 2017, it will raise RMB1.3 billion ($192.5 million) through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company...
23:59 , Dec 28, 2017 |  BC Extra  |  Financial News

Fosun's biosimilar unit to raise $190M

On Dec. 20, Shanghai Henlius Biotech Inc. (Shanghai, China) said it will raise RMB1.3 billion ($192.5 million) through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company Fosun...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
20:12 , Sep 22, 2017 |  BC Week In Review  |  Financial News

AbClon raises W6.8B in IPO

On Sept. 18, AbClon Inc. (KOSDAQ:174900) raised W6.8 billion ($6.1 million) through the sale of 680,741 shares at W10,000 in an IPO. Director Kyu-Tae Kim told BioCentury that AbClon's lead candidate is AC101, a mAb targeting...
19:21 , Sep 19, 2017 |  BC Extra  |  Financial News

AbClon continues to rise after IPO

Korean biotech AbClon Inc. (KOSDAQ:174900) gained W4,050 (16%) to W30,050 in its second day of trading Tuesday. The closing price values the company at W204.4 billion ($183.9 million). On its first day of trading Monday, the...